ATE208374T1 - Beta-laktam und cepham verbindungen und ihre herstellung - Google Patents

Beta-laktam und cepham verbindungen und ihre herstellung

Info

Publication number
ATE208374T1
ATE208374T1 AT93903302T AT93903302T ATE208374T1 AT E208374 T1 ATE208374 T1 AT E208374T1 AT 93903302 T AT93903302 T AT 93903302T AT 93903302 T AT93903302 T AT 93903302T AT E208374 T1 ATE208374 T1 AT E208374T1
Authority
AT
Austria
Prior art keywords
lactam
beta
optionally substituted
production
compound
Prior art date
Application number
AT93903302T
Other languages
English (en)
Inventor
Shigeru Torii
Hideo Tanaka
Mitio Sasaoka
Takashi Shiroi
Yutaka Kameyama
Original Assignee
Otsuka Kagaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03031192A external-priority patent/JP3265381B2/ja
Priority claimed from JP03031092A external-priority patent/JP3227497B2/ja
Application filed by Otsuka Kagaku Kk filed Critical Otsuka Kagaku Kk
Application granted granted Critical
Publication of ATE208374T1 publication Critical patent/ATE208374T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
AT93903302T 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung ATE208374T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP03031192A JP3265381B2 (ja) 1992-02-18 1992-02-18 2−置換メチル−3−セフェム化合物及びその製造法並びに2−エキソメチレンセフェム誘導体の製造法
JP03031092A JP3227497B2 (ja) 1992-02-18 1992-02-18 β−ラクタム化合物及びその製造法
PCT/JP1993/000131 WO1993016043A1 (en) 1992-02-18 1993-02-03 β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF

Publications (1)

Publication Number Publication Date
ATE208374T1 true ATE208374T1 (de) 2001-11-15

Family

ID=26368636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93903302T ATE208374T1 (de) 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung

Country Status (5)

Country Link
US (2) US5470972A (de)
EP (1) EP0592677B1 (de)
AT (1) ATE208374T1 (de)
DE (1) DE69331089T2 (de)
WO (1) WO1993016043A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
ES2384168T3 (es) * 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
RU2342159C2 (ru) * 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
EP3312196B1 (de) 2005-03-23 2019-07-17 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
WO2007019541A2 (en) * 2005-08-08 2007-02-15 Onconon, Llc. Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
US8071323B2 (en) * 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
JP2010534719A (ja) * 2007-07-27 2010-11-11 ファイザー・リミテッド 沈殿化による抗体精製方法
WO2009049086A1 (en) 2007-10-09 2009-04-16 Larry Sutton Broad spectrum beta-lactamase inhibitors
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
US9211302B2 (en) 2011-01-17 2015-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of LRCH4 activity and therapeutic application thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法
JP6403289B2 (ja) 2013-03-12 2018-10-10 グラディウス ファーマシューティカルズ コーポレーションGladius Pharmaceuticals Corporation 誘導体化3−スチリル−セファロスポリン
CA2921398C (en) 2013-08-14 2021-12-14 The Governing Council Of The University Of Toronto Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors
EP3042956A4 (de) 2013-09-05 2017-03-15 University of Miyazaki Spezifisch mit menschlichem integrin a6b4 reagierender antikörper
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. SYK標的治療薬のための抗pSYK抗体分子及びその使用
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
MX2017006485A (es) 2014-11-18 2018-03-23 Janssen Pharmaceutica Nv Anticuerpos anti-cd47, metodos y usos.
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド (エイチケイ) リミテッド 多重特異性Fab融合タンパクおよびその使用
US20190240346A1 (en) 2016-06-20 2019-08-08 Genahead Bio, Inc. Antibody-drug conjugate
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
AU2018300189B2 (en) 2017-07-14 2025-05-15 Pfizer, Inc. Antibodies to MAdCAM
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
JP7410051B2 (ja) 2018-11-20 2024-01-09 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
IT201900008376A1 (it) 2019-06-07 2020-12-07 Univ Degli Studi Di Modena E Reggio Emilia Anticorpi ad attività antitumorale
WO2021045184A1 (ja) 2019-09-04 2021-03-11 株式会社ペルセウスプロテオミクス 多血症治療薬
CN114786718B (zh) 2019-11-27 2025-07-25 株式会社英仙蛋白质科学 癌性腹膜炎的治疗药
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
EP4190813A4 (de) 2020-07-31 2025-02-12 Bio-Thera Solutions, Ltd. Cd47-antikörper und anwendung davon
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
CN117836003A (zh) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 Ros(活性氧类)产生增强剂
CN116333135A (zh) 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
EP4493592A1 (de) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispezifische gpc3xcd28- und gpc3xcd3-antikörper und deren kombination zur gezielten tötung gpc3-positiver maligner zellen
JPWO2023204181A1 (de) 2022-04-19 2023-10-26
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT342197B (de) * 1975-02-20 1978-03-28 Ciba Geigy Ag Neues verfahren zur herstellung von 3-cephemverbindungen
JPS5214789A (en) * 1975-07-22 1977-02-03 Shionogi & Co Ltd Process for preparing 3-substiuted cephem compounds by ring closure
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
EP0124081A3 (de) * 1983-05-02 1986-11-26 Merck & Co. Inc. Substituierte Cephalosporinsulfone mit Antientzündungs- und Antidegenerativwirkung, sie enthaltende Zusammensetzungen und Verfahren zur Herstellung
US5132301A (en) * 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
JPS60237061A (ja) * 1984-05-08 1985-11-25 Otsuka Chem Co Ltd アゼチジノン誘導体の製造法
ATE133954T1 (de) * 1986-11-12 1996-02-15 Merck & Co Inc Substituierte cephalosporinsulfone als anti- entzündliche und anti-degenerative mittel
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
US5162521A (en) * 1991-06-06 1992-11-10 Bristol-Myers Squibb Company Processes for making cephems from allenylazetidinone derivatives

Also Published As

Publication number Publication date
US5470972A (en) 1995-11-28
US5693792A (en) 1997-12-02
DE69331089T2 (de) 2002-07-18
EP0592677B1 (de) 2001-11-07
DE69331089D1 (de) 2001-12-13
EP0592677A1 (de) 1994-04-20
WO1993016043A1 (en) 1993-08-19
EP0592677A4 (en) 1994-07-06

Similar Documents

Publication Publication Date Title
DE69331089D1 (de) Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
DE69020676D1 (de) Tricyclische Carbapenemverbindungen.
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
PT620225E (pt) Derivados de cefalosporina
ATE205199T1 (de) Quinolin- oder quinazolinderivate, deren herstellung und verwendung
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
ATE212027T1 (de) Cephemderivate und verfahren zu ihrer herstellung
DE69121259D1 (de) Beta-Lactam-Verbindungen und ihre Herstellung
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
KR950704333A (ko) 신규한 세펨 유도체(novel cephem derivatives)
ATE244248T1 (de) Herstellung von amino cephalosporansäurederivaten
ATE200674T1 (de) Herstellung von beta-lactamverbindungen und zwischenprodukte
DE3650023D1 (de) Beta-Lactamverbindungen und deren Herstellung.
DE69331249D1 (de) Verfahren zur Herstellung von (1'R,3S,4R)4-Acylthioazetidinonen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee